Key Insights into the Extended-Release Drugs Market: Trends, Growth Rate, and Opportunities Through 2034
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Extended-Release Drugs Market?
The surge in chronic disease cases is anticipated to fuel the expansion of the extended-release drug market in the future. Chronic diseases are those that persist for a year or more, requiring ongoing medical attention, and may disrupt daily activities. Examples include heart disease, cancer, obesity, and diabetes. Extended-release drug delivery mechanisms are engineered to ensure a steadied, invariant level of medication in the body over a longer duration. This enables the consistent therapeutic effects and prevents the fluctuating drug levels associated with immediate-release medications. As an example, in January 2023, the US-based National Center for Biotechnology Information (NCBI), a National Library of Medicine, projected that the number of people aged 50 and above living with at least one chronic disease is set to skyrocket by 99.5% by 2050, reaching a staggering 142.66 million. Hence, the rise in chronic diseases contributes to the upward trend of the extended-release drug market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12675&type=smp
What is the Predicted Annual Growth Rate of the Extended-Release Drugs Market Impact Industry Trends by 2034?
In recent times, the market size of extended-release drugs has seen a rapid expansion. The market, valued at $63.11 billion in 2024, is projected to grow to $70.28 billion in 2025, showing a compound annual growth rate (CAGR) of 11.4%. Factors such as enhanced patient adherence, increased prevalence of chronic diseases, superior efficacy, strategic patent protection, and biodegradable implants have propelled growth in the historical period.
The market size for extended-release drugs is projected to experience a swift expansion in the coming years, and it’s estimated to reach $113.05 billion by 2029, with a compound annual growth rate (CAGR) of 12.6%. Factors contributing to growth in the forecast timeframe may include the rise in personalized medicine, a focus on patient-oriented drug development, the increasing prevalence of lifestyle illnesses, drug repurposing, and worldwide availability of extended-release treatments. Noteworthy trends during this period might encompass pharmaceutical innovation, improved drug delivery systems, nanotechnology advancements, the incorporation of 3d printing into drug formulations, the application of artificial intelligence and environmental sustainability.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12675
What Are the Current Market Growth and Trends in the Extended-Release Drugs Market That Industry Players Should Watch?
Innovation in product development is an emergent trend in the market for extended-release drugs. Dominant businesses in the sector are creating novel products to maintain their market standing. For instance, Zydus Pharmaceuticals (USA) Inc., a manufacturer of generic pharmaceuticals based in the US, unveiled Topiramate extended-release capsules for epilepsy treatment in July 2022. The company had obtained prior approval from the US Food and Drug Administration (USFDA) to market these capsules, with dosages of 25 mg, 50 mg, and 100 mg. It was the first enterprise in the nation to get the final nod and roll out Topiramate extended-release capsules. These capsules, formulated to release Topiramate over an extended period, are approved for use by individuals who have partial onset or primary generalized tonic-clinic seizure.
What Are the Major Market Players Making an Impact on theExtended-Release Drugs Market Growth?
Major companies operating in the extended-release drugs market include Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Eastman Chemical Company, Catalent Pharma Solutions Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, Hisamitsu Pharmaceutical Co. Inc., Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Ardena Holding NV, UPM Pharmaceuticals Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Lavipharm Laboratories Inc., Watson Pharmaceuticals Inc.
Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/extended-release-drugs-global-market-report
How Are the Key Segments of the Extended-Release Drugs Market Driving Opportunities and Innovations?
The extended-release drugs market covered in this report is segmented –
1) By Type: Sustained Release Drug, Controlled Release Drug
2) By Mode: Over-The-Counter, Prescription
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores
Subsegments:
1) By Sustained Release Drug: Matrix Systems, Coating Systems
2) By Controlled Release Drug: Osmotic Systems, Microencapsulation Systems, Targeted Delivery Systems
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12675&type=smp
What Regions Are At the Forefront of #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theExtended-Release Drugs Market?# Market Expansion?
North America was the largest region in the extended-release drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the extended-release drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Reports Similar to the Gobal Extended-Release Drugs Maret 2025, By The Business Research Company:
Controlled Release Fertilizer Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/controlled-release-fertilizer-global-market-report
Drugs of Abuse (DOA) Testing Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/drugs-of-abuse-doa-testing-global-market-report
Drugs For Benign Prostatic hypertrophy Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
